期刊文献+

Do newer antihypertensives play better than older ones?——Lessons learned from the ASCOT-BPLA trial

Do newer antihypertensives play better than older ones?—Lessons learned from the ASCOT-BPLA trial
原文传递
导出
摘要 Hypertension has currently become a centennial epidemic and key public health problem inChina. According to an investigation among 15 540 adults from 2000 to 2001 by Gu and co-workers,1 the prevalence of hypertension among people aged 35 to 74 years has reached 27. 2%, ranking among the highest rates of hypertension in the world and putting the blood pressure (BP) of nearly 130 million Chinese adults above the normal level. A latest survey by the Beijing Municipal Health Bureau showed that among residents in Beijing aged 15 years old and above, the incidence of hypertension has climbed up to 25%, and among residents at and above 45 years old in the city, it has exceeded 50%. Hypertension has currently become a centennial epidemic and key public health problem inChina. According to an investigation among 15 540 adults from 2000 to 2001 by Gu and co-workers,1 the prevalence of hypertension among people aged 35 to 74 years has reached 27. 2%, ranking among the highest rates of hypertension in the world and putting the blood pressure (BP) of nearly 130 million Chinese adults above the normal level. A latest survey by the Beijing Municipal Health Bureau showed that among residents in Beijing aged 15 years old and above, the incidence of hypertension has climbed up to 25%, and among residents at and above 45 years old in the city, it has exceeded 50%.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2005年第21期1763-1765,共3页 中华医学杂志(英文版)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部